289032-37-7

Usage

Also known as

benzhydryl valeraldehyde

Classification

aromatic aldehyde

Mains uses

fragrance and flavoring agent, production of synthetic flavors and perfumes

Odor

strong, sweet, floral, jasmine-like

Additional uses

reagent in organic synthesis, formulation of various chemical products

Regulation

due to potential health and environmental hazards

Upstream product

• 1155663-08-3 ethyl 5-(biphenyl-4-yl)pentanoate 
• 16913-50-1 (2E,4E)-ethyl 5-(biphenyl-4-yl)penta-2,4-dienoate 
• 3218-36-8 4-Phenylbenzaldehyde 
• 120756-57-2 4-(5-hydroxypentyl)-1,1'-biphenyl 

Relevant academic research and scientific papers

Rhodium-Catalyzed Remote C(sp3)?H Borylation of Silyl Enol Ethers

A rhodium-catalyzed remote C(sp3)?H borylation of silyl enol ethers (SEEs, E/Z mixtures) by alkene isomerization and hydroboration is reported. The reaction exhibits mild reaction conditions and excellent functional-group tolerance. This method is compatible with an array of SEEs, including linear and branched SEEs derived from aldehydes and ketones, and provides direct access to a broad range of structurally diverse 1,n-borylethers in excellent regioselectivities and good yields. These compounds are precursors to various valuable chemicals, such as 1,n-diols and aminoalcohols.

Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations

Inhibition of group IIA secreted phospholipase A2 (GIIA sPLA2) has been an important objective for medicinal chemists. We have previously shown that inhibitors incorporating the 2-oxoamide functionality may inhibit human and mouse GIIA sPLA2s. Herein, the development of new potent inhibitors by molecular docking calculations using the structure of the known inhibitor 7 as scaffold, are described. Synthesis and biological evaluation of the new compounds revealed that the long chain 2-oxoamide based on (S)-valine GK241 led to improved activity (IC50 = 143 nM and 68 nM against human and mouse GIIA sPLA2, respectively). In addition, molecular dynamics simulations were employed to shed light on GK241 potent and selective inhibitory activity.

DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR

This invention provides new chemical entities useful for treating a variety of clinical disorders including those that areinfluenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5-adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.